Human PDE6C (GenBank Accession No. NM_006204), full length, with N-terminal GST-tag, MW=125 kDa, expressed in a Baculovirus infected Sf9 cell expression system.

P51160

PDE6C, phosphodiesterase 6C

≥ 3,000 pmol/min/µg

One unit is defined as the amount of enzyme that will convert 1 pmole of 3', 5'-cGMP to 5'-GMP per minute at 37°C.

10 mM Tris-HCl, pH 7.4, 10 mM MgCl₂, 0.1 mg/ml BSA, 0.05% Tween-20, 200 µM cGMP, 2.5 kU 5'-nucleotidase, and serial dilutions of PDE6C at 37°C for 60 min. Quantified by 5'- nucleotidase cleaving the 5' -GMP product and releasing the phosphate group which is detected by Malachite Green Reagent.

40 mM Tris-HCl, pH 8.0, 110 mM NaCl, 2.2 mM KCL, 3 mM DTT, 20% Glycerol and 2 mM Glutathione.

Aqueous buffer solution

>6 months at -80°C.

Useful for the study of enzyme kinetics, screening inhibitors, and selectivity profiling.

1. Martinez S.E. et al., J Biol Chem. 2008 Sep 19;283(38):25913-9.
2. Stearns G. et al., J Neurosci. 2007 Dec 12;27(50):13866-74.

Application Reference(s):
1. Design and Synthesis of Novel and Selective Phosphodiesterase 2 (PDE2a) Inhibitors for the Treatment of Memory Disorders (2017)
2. Discovery of Selective Phosphodiesterase 1 Inhibitors with Memory Enhancing Properties (2017)
3. Novel N-hydroxybenzamides incorporating 2-oxoindoline with unexpected potent histone deacetylase inhibitory effects and antitumor cytotoxicity. (2017)

This product is a more active version of former BPS Cat. #60060.

Avoid freeze/thaw cycles.

PDE

Recombinant Protein